biostudies-literatureXuzhang WShanghai Municipal Health Commissioncollaborative innovation center for cardiovascular disease translational medicinescience and technology commission of shanghai municipalityshanghai chest hospitalNational Natural Science Foundation of Chinanatural science foundation of shanghaiprogram of shanghai academic research leaderClinical Research Plan of SHDCnational key research and development program of china17588359231156387https://www.ebi.ac.uk/biostudies/studies/S-EPMC9989452biostudies-literatureUnknown15<h4>Background</h4>Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (IO) resistance in advanced non-small-cell lung cancer (NSCLC), especially in personalized therapies for patients with different oligoprogressive patterns.<h4>Methods</h4>Based on European Society for Radiotherapy and Oncology/European Organization for Research and Treatment of Cancer consensus, metastatic NSCLC patients with cancer progression after IO resistance were divided into four patterns, repeat oligoprogression (REO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (INO, oligoprogression Therapeutic advances in medical oncologyTreatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.PMC9989452174319061038207256416CR3005ATM202112SHDC2020CR5001YJXT2019020922XD14228020ZR1452000CCTS202204YJXT201901052016YFC1303300820300452022XD0291941195050082241227Shen LLi ZHuang HLu SXuzhang WYu YfalseTreatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.<h4>Background</h4>Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (IO) resistance in advanced non-small-cell lung cancer (NSCLC), especially in personalized therapies for patients with different oligoprogressive patterns.<h4>Methods</h4>Based on European Society for Radiotherapy and Oncology/European Organization for Research and Treatment of Cancer consensus, metastatic NSCLC patients with cancer progression after IO resistance were divided into four patterns, repeat oligoprogression (REO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (INO, oligoprogression 2023-01-01T00:00:00Z20232026-05-13T14:27:25.759Z2025-02-19T03:26:20.967ZS-EPMC99894523689585310.1177/17588359231156387